Medprin Regenerative Medical Technologies Co. Ltd. (301033) — Working Capital to Net Assets Ratio
Medprin Regenerative Medical Technologies Co. Ltd. (301033) has a Working Capital to Net Assets ratio of 34.8% as of June 2025. Working capital of CN¥249.55 Million (current assets of CN¥289.60 Million minus current liabilities of CN¥40.05 Million) is measured against net assets of CN¥716.31 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Medprin Regenerative Medical Technologie balance sheet independence to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Medprin Regenerative Medical Technologies Co. Ltd. Working Capital to Net Assets (2019–2024)
This chart shows how Medprin Regenerative Medical Technologies Co. Ltd.'s Working Capital to Net Assets ratio has evolved across 6 annual periods from 2019 to 2024. As of June 2025, the ratio stands at 34.8%, reflecting working capital of CN¥249.55 Million against net assets of CN¥716.31 Million CNY. Check 301033 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Medprin Regenerative Medical Technologies Co. Ltd. (2019–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Medprin Regenerative Medical Technologies Co. Ltd. from 2019 to 2024, covering 6 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market cap of Medprin Regenerative Medical Technologie.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 37.9% | CN¥264.93 Million | CN¥699.66 Million | CN¥312.41 Million | CN¥47.48 Million | ▲ +6.2 pp |
| 2023 | 31.7% | CN¥201.59 Million | CN¥635.86 Million | CN¥269.71 Million | CN¥68.12 Million | ▲ +5.7 pp |
| 2022 | 26.0% | CN¥156.48 Million | CN¥602.58 Million | CN¥238.25 Million | CN¥81.77 Million | ▼ -37.1 pp |
| 2021 | 63.0% | CN¥362.96 Million | CN¥575.87 Million | CN¥417.14 Million | CN¥54.18 Million | ▲ +5.5 pp |
| 2020 | 57.5% | CN¥194.43 Million | CN¥338.07 Million | CN¥252.56 Million | CN¥58.13 Million | ▼ -5.2 pp |
| 2019 | 62.7% | CN¥189.75 Million | CN¥302.78 Million | CN¥222.88 Million | CN¥33.13 Million | — |